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Abstract  
Background 
The natural history of chronic hepatitis B virus (HBV) infection in sub-Saharan Africa is 
unknown. Data is required to inform WHO guidelines which are currently based on studies in 
Europe and Asia. 
Methods 
Between 1974 and 2008, sero-surveys were repeated in two Gambian villages, and an open 
cohort of treatment-naïve chronic HBV carriers was recruited. Participants were followed to 
estimate the rates of hepatitis B e (HBeAg) and surface antigen (HBsAg) clearance and 
incidence of hepatocellular carcinoma (HCC). In 2012-2013, a comprehensive liver 
assessment was conducted to estimate the prevalence of severe liver disease.  
Results 
405 chronic carriers (95% genotype E), recruited at a median age of 10.8 years, were followed 
for a median length of 28.4 years. Annually, 7.4% (95% CI: 6.3-8.8%) cleared HBeAg and 
1.0% (0.8-1.2%) cleared HBsAg. The incidence of HCC was 55.5/100,000 carrier-years (95% 
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CI: 24.9-123.5). In the 2012-2013 survey (n=301), 5.5% (95% CI: 3.4-9.0%) had significant 
liver fibrosis. HBV genotype A (versus E), chronic aflatoxin B1 exposure, and an HBsAg-
positive mother, a proxy for mother-to-infant transmission, were risk factors for liver fibrosis. 
A small proportion (16.0%) of chronic carriers were infected via mother-to-infant 
transmission, however, this population represented a large proportion (63.0%) of the cases 
requiring antiviral therapy.  
Conclusions 
The incidence of HCC amongst chronic HBV carriers in West Africa was higher than that in 
Europe but lower than rates in East Asia. High risk of severe liver disease amongst the few 
who are infected by their mothers underlines the importance of interrupting perinatal 
transmission in sub-Saharan Africa. 
  
Summary Box 
What is already known about this subject? 
- Chronic hepatitis B virus infection is a common cause of liver disease in sub-Saharan 
Africa. 
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- Although the WHO recently published its first HBV treatment guidelines with a main 
focus on resource-limited countries, their recommendations are based on Western and 
Asian studies, since there have been no natural history data from sub-Saharan Africa. 
- Mother-to-infant transmission is a risk factor for chronic HBV infection, however, it is 
unclear whether this mode of transmission further increases the risk of severe liver 
disease in chronic carriers. 
What are the new findings? 
- The incidence rate of hepatocellular carcinoma (HCC) in treatment-naïve male chronic 
HBV carriers in The Gambia was higher than Europe but lower than in East Asia. 
- Mother-to-infant transmission was a risk factor for persistent viral replication, elevated 
transaminase, significant fibrosis and HCC. 
- The majority (63.0%) of cases requiring antiviral therapy were attributable to maternal 
transmission. 
- Among chronic HBV carriers, genotype A (versus E) and chronic exposure to 
aflatoxin B1 were associated with an elevated risk of significant liver fibrosis. 
How might it impact on clinical practice in foreseeable future? 
- The disproportionate risk of severe liver disease amongst people who acquired HBV 
from their mothers emphasizes the importance of interrupting perinatal transmission in 
sub-Saharan Africa. 
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INTRODUCTION 
In sub-Saharan Africa (SSA) chronic hepatitis B virus (HBV) infection is a major public 
health problem, which causes an estimated 61,000 deaths due to cirrhosis or hepatocellular 
carcinoma (HCC) each year [1]. Before the introduction of hepatitis B vaccine, >70% of 
African children were exposed to HBV at birth or during childhood and 10-20% became 
chronic HBV carriers [2]. Currently, all African countries have integrated hepatitis B vaccine 
into their Expanded Program on Immunization (EPI).  
Despite its efficacy in preventing chronic HBV infection, vaccination has several limitations 
as a control strategy. First, a large number of people who were infected prior to the 
vaccination programs are left with chronic HBV infection [3]. Second, hepatitis B vaccine 
does not always prevent mother-to-infant transmission [4], especially when the vaccine is not 
given at birth [5]. Though this mode of transmission is less frequent than horizontal 
transmission in SSA [6], the risk of HCC may be higher in vertically-transmitted chronic 
infections [7–9]. 
To overcome these limitations, antiviral therapy can be used to prevent HBV-related disease 
in cases of chronic HBV infection and also to prevent vertical HBV transmission. In March 
2015, the World Health Organization (WHO) issued its first guidelines on chronic HBV 
infection to improve access to antiviral therapy in low- and middle-income countries. 
However, their recommendations are based on the findings from Asia, Europe and North 
America, since there have been no natural history data from SSA [3]. Understanding the 
natural history of chronic HBV infection is essential to inform decisions about who to treat 
and when to treat [3]. 
Page 9 of 86
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 
10 
 
The UK Medical Research Council (MRC), the International Agency for Research on Cancer 
(IARC/WHO) and the Gambia Government have been supporting studies on HBV infection 
in The Gambia since the 1980’s, and have established a population-based open cohort of 
treatment-naïve chronic HBV carriers. We used this cohort to describe the natural history of 
chronic HBV infection: i) the sero-clearance rates of hepatitis B e antigen (HBeAg) and 
surface antigen (HBsAg); ii) the incidence of HCC, end-stage liver disease (ESLD) and all-
cause mortality; iii) longitudinal changes in serum HBV DNA and alanine transaminase (ALT) 
levels; and iv) the prevalence of significant liver fibrosis and chronic liver disease requiring 
antiviral therapy according to the European Association for the Study of the Liver (EASL) [10] 
or the WHO guidelines [3]. We also estimated the HBV-related disease burden attributable to 
the mother-to-infant transmission in SSA by examining the associations between these 
outcomes and maternal HBsAg, a proxy for mother-to-infant HBV transmission [8].  
 
METHODS 
Participants 
The cohort of chronic HBV carriers was recruited from Keneba and Manduar, two 
neighboring villages in West Kiang District. They are typical of many African rural 
communities where Mandinka and Jola people live in mud or lath-and-plaster houses roofed 
with thatch or corrugated iron with subsistence agriculture [11]. Primary health care has been 
available free of charge at the MRC Keneba Clinic. Baseline HBV sero-surveys were 
undertaken in 1974 and in 1980. In the first survey the entire population was surveyed 
(n=1,317) and 13.2% were found to carry HBsAg [11] while the second survey was limited to 
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children aged <15 years and their mothers (n=802) [12]. Following the third sero-survey in 
1984 [13], all non-immune children in Keneba/Manduar were invited to participate in an 
HBV vaccine trial [14]. Hepatitis B vaccination was introduced in the EPI in 1990 with a 
vaccine schedule starting at birth. Hepatitis B immunoglobulin has been unavailable. Between 
1985 and 2008, sero-surveys to measure the vaccine efficacy were repeated every 4-5 years 
[4,14–17]. In parallel, those who had been tested HBsAg-positive were followed for HBV 
sero-markers in 1985, 1989, 1992, 1993, 1998, 2003, and 2008 (supplementary table 1). 
Survey participation was 92-100% and 50-85% in those aged 0-9 and 10-19 years, 
respectively [12–15].   
Liver assessment in 2012-2013 
Following community approval, people with chronic HBV infection in the cohort were invited 
to a liver assessment as part of the PROLIFICA (Prevention of Liver Fibrosis and Cancer in 
Africa) project [18]. Chronic infection was defined as serum HBsAg positivity at two visits at 
least six months apart. In individuals aged ≥13 years, HBsAg positivity at only one visit was 
considered as chronic infection because, in the pre-vaccination era, 90% of children in 
Keneba/Manduar acquired the infection by the age of 13 years and new infections were 
uncommon beyond this age [13]. After written informed consent, participants, who had fasted 
overnight, underwent a standardized clinical examination that involved blood collection, 
abdominal ultrasound and liver stiffness measurement using transient elastography (Fibroscan, 
Echosens, France). Those with serum HBV DNA ≥2,000 IU/ml or liver stiffness ≥6.5 kPa or 
ALT ≥40 IU/L, were invited for liver biopsy. Histopathologists in UK scored liver fibrosis 
using Metavir system [19]. The study was approved by the Gambia Government/MRC Joint 
Ethics Committee and conducted according to the guidelines of the Declaration of Helsinki. 
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Laboratory assays 
HBsAg was detected by radioimmunoassay (Ausria-I, Abbott, USA) in 1974 [12], reverse 
passive hemagglutination assay (Wellcotest, Wellcome Diagnostics, UK) in 1980-1998 [15], 
immunochromatography (Determine, Abbott) in 2003-2008 [20], and chemiluminescent 
microparticle immunoassay (Architect, Abbott) in 2012-2013 [21]. HBsAg-positive samples 
were tested for HBeAg by radioimmunoassay in 1980-1998 [15] and later by enzyme 
immunoassay (EIA) (Diasorin, Biomedica, Italy) [20]. The serological tests were strongly 
correlated with one another [20,21]. HBV DNA levels were measured at the end of the study 
in stored samples collected in 1984, 1989, 1993, 2003, 2008, and 2012-2013, using in-house 
quantitative real-time polymerase chain reaction (detection limit: 50 IU/ml), calibrated against 
an international standard [22]. As previously reported, samples collected in 2003 were 
examined for HBV genotype and an AGG→AGT mutation at codon 249 of p53 tumor 
suppressor gene (p53R249S) in cell-free DNA, a biomarker of chronic aflatoxin B1 exposure 
[23]. Samples collected in 2012-2013 were tested for alpha-fetoprotein and antibodies to 
Hepatitis C virus (HCV) using microparticle EIA (AxSYM, Abbott), antibodies to Hepatitis D 
virus (HDV) using EIA (ETI-AB-DELTAK-2, Diasorin), and antibodies to HIV-1/2 and p24 
antigen using EIA (Genscreen-ULTRA, Bio-Rad, USA). Schistosoma mansoni infection is 
rare in The Gambia [24] and therefore was not investigated.  
Ascertainment of liver disease and death 
Significant liver fibrosis, severe fibrosis and cirrhosis was defined as ≥F2, ≥F3 and F4 
(Metavir) for those who had liver histopathology and liver stiffness ≥7.9, ≥8.2 and ≥9.5 kPa 
for those without biopsy. These cut-offs were determined by our validation study in The 
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Gambia, where the sensitivity of Fibroscan to predict ≥F2 was 81% and the specificity was 81% 
[25]. The EASL criteria for antiviral therapy are: i) viral load ≥2,000 IU/ml and significant 
fibrosis, or  ii) viral load ≥2,000 IU/ml and moderate/severe active necroinflammation (≥A2 
by Metavir activity grade), or iii) viral load ≥20,000 IU/ml and ALT ≥80 IU/L, or iv) 
detectable viral load and cirrhosis [10]. The WHO criteria are: i) clinically diagnosed cirrhosis, 
or ii) aspartate transaminase (AST)-to-platelet ratio index (APRI) >2.0, or iii) ≥30 years old 
and abnormal ALT and HBV DNA >20,000 IU/ml [3]. The phases of the natural history of 
chronic HBV infection were described [10,26] for the baseline and 2012-2013 survey 
(supplementary table 2). 
HCC cases were identified through a follow-up examination, review of medical records in the 
MRC Keneba Clinic, or by data linkage with the Gambia National Cancer Registry [27]. The 
diagnosis was based on the identification of a focal hepatic lesion consistent with HCC on the 
ultrasound and elevated serum alpha-fetoprotein (≥200 ng/ml). ESLD includes HCC and non-
malignant ESLD. The latter was defined as cirrhosis without HCC and the presence of ascites, 
hepatic encephalopathy, or hematemesis. The date of death was ascertained through a review 
of the medical chart in the MRC or data linkage with the West Kiang Demographic 
Surveillance System [28].  
Statistical analyses  
The person-years of follow-up for HBeAg/HBsAg clearance, HCC, ESLD, or death were 
calculated from the date they were identified as HBsAg-positive to the date of endpoint or last 
follow-up, whichever came first. The date of sero-clearance was defined as the midpoint 
between the last positive and the first negative result. The cumulative incidence was estimated 
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as a function of age using the Kaplan-Meier Method. Age was used rather than time since 
entry into the study because most infections occur during early childhood [13], and therefore 
age approximates the duration of HBV infection. The associations between maternal HBsAg, 
as recorded at the recruitment of the child, and the HBeAg/HBsAg loss were examined using 
Poisso  regression with robust standard error to account for clustering in children that share 
the same mother. The models included current age, calendar year, sex, and birthplace as 
covariates. The effect of maternal HBsAg on ALT and HBV DNA (log10 transformed) was 
quantified using a linear mixed model with random intercept and random slope to account for 
the multiple measurements made on the same individuals over time. The detection limit of the 
assay was assigned to samples with undetectable viral load. The effect of maternal HBsAg on 
significant fibrosis and meeting antiviral treatment criteria was estimated using logistic 
regression to control for age, sex, and birthplace (partial model), and additionally for HBV 
genotype and p53R249S (full model). 
Population attributable fractions were calculated [29] for the effects of maternal sero-status on 
chronic HBV infection and HBV-related liver disease (significant fibrosis and meeting the 
EASL treatment criteria). This analysis included all the survey participants (1974-2008) with 
available maternal sero-status who did not receive hepatitis B vaccine. It was not restricted to 
chronic carriers so that the twofold effect of mother-to-infant transmission could be estimated, 
i.e., the increased risk of both chronic infection [30], and of liver disease progression in those 
with established chronic infection [8,9]. All analyses were performed using STATA 11.0 
(Stata Corporation, USA). 
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RESULTS 
Baseline characteristics 
Between 1974 and 2008, 551 villagers tested positive for HBsAg at least once in the 
Keneba/Manduar sero-surveys. None had HCC at enrolment. Twenty-nine HBsAg-positive 
villagers did not participate in any subsequent sero-surveys. These individuals did not differ 
from the rest of HBsAg-positive individuals in sex, age, HBeAg, HBV DNA and ALT levels 
at baseline. Finally, there were 405 chronic carriers (figure 1). The median length of follow-
up was 28.4 years (IQR: 17.7-32.7) with the median number of six sero-surveys (IQR: 3-8). 
The median age at recruitment was 10.8 years (IQR: 4.6-21.8). Half were male, and 65.2%, 
26.1%, and 8.7% had a mother who was HBsAg-negative, HBsAg-positive/HBeAg-negative, 
and HBsAg-positive/HBeAg-positive, respectively (table 1). The children of positive mothers 
had high viral load (p=0.04) and abnormal ALT levels (p=0.05) at baseline. Thirty became 
chronic carriers despite having been fully vaccinated against HBV; median age at the first 
vaccine was 34 days and none received within three days of birth, and the majority (60.9%, 
14/23) had HBsAg-positive mothers. In the 2003 sero-survey, 95.1% (97/102) had genotype E 
and the rest genotype A; 44.2% (100/226) had the p53R249S mutation [23].  
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Table 1. Baseline characteristics of people with chronic HBV infection by maternal HBsAg 
status (N=405) 
Variables All (N=405) Unknown 
maternal 
sero-status 
(n=152) 
With 
HBsAg(+) 
mother 
(n=88) 
With 
HBsAg(-) 
mother 
(n=165) 
p-
value1 
 
Sex Male 204 (50%) 63 (41%) 48 (55%) 93 (56%) 0.8 
Female 201 (50%) 89 (59%) 40 (45%) 72 (44%)  
Age group 
(years) 
<5 109 (27%) 4 (3%) 42 (48%) 63 (38%) 0.92 
5 – 9 83 (20%) 9 (6%) 22 (25%) 52 (32%)  
10 – 14 56 (14%) 16 (10%) 8 (9%) 32 (19%)  
15 – 19 39 (10%) 23 (15%) 5 (6%) 11 (7%)  
≥20 118 (29%) 100 (66%) 11 (12%) 7 (4%)  
Birth place Keneba 233 (58%) 106 (70%) 39 (44%) 88 (53%) 0.4 
Manduar 172 (42%) 46 (30%) 49 (56%) 77 (47%)  
Hepatitis 
B vaccine 
Never 375 (93%) 145 (95%) 74 (84%) 156 (95%) 0.02 
Ever 30 (7%) 7 (5%) 14 (16%) 9 (5%)  
HBeAg Negative 213 (55%) 118 (86%) 30 (34%) 65 (40%) 0.4 
Positive 173 (45%) 19 (14%) 58 (66%) 96 (60%)  
HBV 
DNA 
(IU/ml) 
<2,000 222 (57%) 121 (83%) 30 (35%) 71 (45%) 0.042 
2,000-108 90 (23%) 20 (14%) 19 (22%) 51 (32%)  
≥108 79 (20%) 5 (3%) 37 (43%) 37 (23%)  
ALT 
(IU/L) 
<40 367 (94%) 134 (92%) 77 (91%) 156 (97%) 0.05 
≥40 25 (6%) 12 (8%) 8 (9%) 5 (3%)  
Phase of 
natural 
history 
Immune 
tolerant 
116 (29%) 8 (5%) 42 (48%) 66 (40%) 0.1 
HBeAg(+) 
chronic 
hepatitis 
14 (3%) 5 (3%) 7 (8%) 2 (1%)  
HBeAg(-) 
chronic 
hepatitis 
11 (3%) 7 (5%) 1 (1%) 3 (2%)  
Inactive carrier 190 (47%) 117 (77%) 22 (25%) 51 (31%)  
Unclassified 74 (18%) 15 (10%) 16 (18%) 43 (26%)  
HBV 
genotype3 
Genotype A 5 (5%) 1 (3%) 2 (8%) 2 (5%) 0.6 
Genotype E 97 (95%) 33 (97%) 24 (92%) 40 (95%)  
p53R249S 
mutation3 
Negative 126 (56%) 50 (63%) 23 (44%) 53 (56%) 0.1 
Positive 100 (44%) 30 (37%) 29 (56%) 41 (44%)  
Median no. of follow-up 
sero-surveys (IQR) 
6 (3, 8) 4 (3, 6) 6 (4, 8) 7 (5, 8) 0.1 
Median years of follow-up 
(IQR) 
28.4 (17.7, 
32.7) 
24.4 (10.2, 
37.9) 
28.6 (16.0, 
32.0) 
28.7 (23.8, 
32.1) 
0.2 
1 Comparison was made between participants with HBsAg-positive mothers and HBsAg-
negative mothers. P-value and 95% CI were obtained by Wald test with robust standard error. 
2 Linear test for trend 
3 Determined in a subset of participants in 2003 
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HBeAg sero-clearance 
At the enrolment, 213 (52.6%) chronic carriers had already lost HBeAg, The age-specific 
prevalence of HBeAg at baseline decreased with increasing age (supplementary figure 1). Of 
the 173 HBeAg-positive carriers at baseline, 82.1% lost HBeAg and the clearance rate was 
7.4%/year (95% CI: 6.3-8.8) (table 2, figure 2). Fifteen experienced HBeAg reversion, nine of 
whom eventually lost HBeAg whilst six continued to carry HBeAg until the last follow-up. 
After adjusting for sex, current age, calendar year and birthplace, the sero-clearance rate was 
slower in carriers with high HBV DNA levels (≥108 IU/ml) at baseline (supplementary table 
3). Carriers with HBsAg-positive mothers tend to clear HBeAg slowly, although this did not 
reach statistical significance (supp ementary figure 2-A).  
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Table 2. Incidence rates of HBeAg and HBsAg sero-clearance, HCC, ESLD and all-cause 
mortality in people with chronic HBV infection by gender 
Event No. of 
subjects 
Person-years 
at risk 
No. of 
events 
Rate 95% CI 
HBeAg clearance 173 1912 142 7.4 / 100  6.3 – 8.8 
  Male   109   1231   86   7.0   5.7 – 8.6 
  Female   64   681   56   8.2   6.3 – 10.7 
HBsAg clearance 405 8502 85 1.00 / 100  0.81 – 1.24 
  Male   204   4076   32   0.79   0.56 – 1.11 
  Female   201   4426   53   1.20   0.91 – 1.57 
HCC 405 10815 6 55.5 / 100,000  24.9 – 123.5 
  Male   204   5200   6   115.4   51.8 – 256.8 
   Boys (<20 y.o.)   1930  0  0.0  N/A 
   Adult men (≥20 y.o.)   3270  6  183.5  82.4 – 408.5 
  Female   201   5615   0   0.0   N/A 
ESLD (including HCC) 405 10815 8 74.0 / 100,000 37.0 – 147.9 
  Male   204   5200   7   134.6   64.2 – 282.4 
  Female   201   5615   1   17.8   2.5 – 126.4 
All-cause mortality 405 10815 43 397.6 / 100,000  294.9 – 536.1 
  Male   204   5200   25   480.8   324.9 – 711.5 
  Female   201   5615   18   320.6   202.0 – 508.8 
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HBsAg sero-clearance 
The rate of HBsAg sero-clearance was 1.0%/year (95% CI: 0.8-1.2) (table 2) with half 
clearing by 57 years old (figure 2). Younger age and high HBV DNA levels at baseline were 
associated with delayed HBsAg sero-clearance (supplementary table 4). The sero-clearance 
rate was slower in carriers with HbsAg-positive mothers, but this was not statistically 
significant (supplementary figure 2-B). 
HCC, ESLD, and mortality 
Of the 405 chronic carriers, 43 died; the all-cause mortality rate was 397.6/100,000 person-
years (95% CI: 294.9-536.1). The most common cause of death was HCC (24.0%) in men and 
bacterial infection (22.2%) in women. All patients with ESLD (including HCC (n=6) and 
non-malignant ESLD (n=2)) died within one year of diagnosis. Incidence rates of HCC and 
ESLD were 55.5 (95% CI: 24.9-123.5) and 74.0 (95% CI: 37.0-147.9) per 100,000 person-
years, respectively (table 2). All HCC patients were men, all but one was HBeAg-negative at 
enrolment, and their age at diagnosis ranged between 38 and 67 years (supplementary table 5). 
The HCC incidence in men ≥20 years was 183.5 (95% CI: 82.4-408.5) per 100,000 person-
years. Maternal sero-status was available in three ESLD patients, and all had HBsAg-positive 
mothers. Crude incidence rates of HCC in carriers with HBsAg-positive mothers was 
89.2/100,000 (95% CI: 22.3-356.8) while those with negative mothers was 0/100,000 
(unadjusted p<0.001). 
Mean HBV DNA and ALT over time 
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The trajectories of HBV DNA and ALT levels by maternal HBsAg are presented in figure 3. 
Viral load decreased with increasing age at measurement whilst ALT increased. Both viral 
load and ALT were higher in men than women (supplementary table 6). After adjusting for 
confounders, the geometric mean viral load was 4.7 times higher (95% CI: 2.0-11.1, p<0.001) 
and mean ALT was 4.0 IU/L higher (95% CI: 1.2-6.8, p=0.005) in carriers with HBsAg-
positive mothers than in those with HBsAg-negative mothers.  
Prevalence of chronic liver disease in 2012-2013 
After excluding those who died, 83.1% (301/362) of chronic HBV carriers participated in the 
liver assessment in 2012-2013 (figure 1). Participation was lower in men than women, in 
younger than in older age groups and in carriers with positive HBeAg at baseline compared 
with those HBeAg-negative. Table 3 presents the characteristics of the participants. None had 
ever received antiviral or immunosuppressive therapy. The number co-infected with HIV, 
HCV, and HDV was three, one, and one, respectively. None had alcohol intake >20 g/day 
based on the standardized questionnaire. Between the baseline and 2012-2013 survey, the 
proportion of carriers in the immune tolerant phase decreased from 28.6% to 2.3% whilst the 
proportion in the inactive phase increased from 46.9% to 64.5% (tables 1 and 3, 
supplementary figure 3). Only 6.3% were in HBeAg-negative chronic hepatitis in 2012-2013. 
Thirty participants had a liver biopsy and 269 had a valid measurement using transient 
elastography. No liver specimen had steatosis. Fifteen carriers (5.5%, 95% CI: 3.4-9.0%) had 
significant fibrosis, including nine with severe fibrosis and one with cirrhosis. After 
controlling for confounders, male gender, genotype A, p53R249S mutation, persistence of 
HBeAg, high viral load, and ALT were risk factors for significant fibrosis (table 4). After 
adjusting for sex, age, birthplace, HBV genotype and p53R249S, the odds ratio (OR) for the 
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effect of maternal HBsAg on significant fibrosis was 15.8 (95% CI: 1.4-174.1, p=0.02). 
Eleven participants (3.7%, 95% CI: 2.0-6.5%) met the EASL treatment criteria. Carriers with 
an HBsAg-positive mother, HBeAg persistence, frequent high viral load, and abnormal ALT 
were more likely to require antiviral therapy (table 4). Only five participants (1.7%, 95% CI: 
0.7-3.9%) fulfilled the WHO treatment criteria. 
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Table 3. Characteristics of people with chronic HBV infection who participated in the liver 
assessment 2012-2013 by maternal HBsAg status (N=301) 
Variables All (N=301) With HBsAg(+) 
mother (n=66) 
With HBsAg(-) 
mother (n=123) 
p-
value1 
Sex Male 130 (43%) 32 (48%) 59 (48%) 0.9 
Female 171 (57%) 34 (52%) 64 (52%)  
Current 
age group 
(years) 
<30 46 (15%) 17 (26%) 18 (14%) 0.82 
30 – 39 117 (39%) 30 (45%) 66 (54%)  
40 – 49 57 (19%) 8 (12%) 28 (23%)  
≥50 81 (27%) 11 (17%) 11 (9%)  
Birth 
place 
Keneba 178 (59%) 27 (41%) 65 (53%) 0.3 
Manduar 123 (41%) 39 (59%) 58 (47%)  
ALT in 
2012/2013 
<40 IU/L 268 (91%) 54 (84%) 110 (93%) 0.08 
≥40 IU/L 25 (9%) 10 (16%) 8 (7%)  
HBV 
marker in 
2012/2013 
HBsAg(+), HBeAg(+) 14 (5%) 6 (9%) 6 (5%) 0.32 
HBsAg(+), HBeAg(-) 227 (75%) 53 (80%) 100 (81%)  
HBsAg(-) 60 (20%) 7 (11%) 17 (14%)  
HBV 
DNA 
(IU/ml) in 
2012/2013 
Undetectable 135 (47%) 23 (35%) 59 (50%) 0.022 
50-200 65 (22%) 16 (24%) 26 (22%)  
200-2,000 57 (20%) 13 (20%) 23 (19%)  
2,000-20,000 11 (4%) 4 (6%) 4 (3%)  
≥20,000 20 (7%) 10 (15%) 7 (6%)  
Phase of 
natural 
history in 
2012/2013 
Immune tolerant 7 (2%) 2 (3%) 4 (3%) 0.8 
HBeAg(+) chronic 
hepatitis 
4 (1%) 4 (6%) 0 (0%)  
HBeAg(-) chronic 
hepatitis 
19 (6%) 6 (9%) 7 (6%)  
Inactive carrier 194 (65%) 41 (62%) 88 (71%)  
Occult HBV 12 (4%) 2 (3%) 5 (4%)  
Resolved hepatitis B 48 (16%) 5 (8%) 12 (10%)  
Unclassified 17 (6%) 6 (9%) 7 (6%)  
1 p-value from Wald test with robust standard error to take account of clustering among 
individuals who share the same mother. 
2 Linear test for trend 
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Table 4. Factors associated with significant liver fibrosis (n=271)1 and condition fulfilling the EASL treatment criteria (n=301) among people 
with chronic HBV infection who participated in the liver assessment 2012-13 
Variables Significant liver fibrosis (n=271) Meeting the EASL treatment criteria (n=301) 
Proportion 
(%) 
Crude OR Adjusted OR3 Proportion 
(%)  
Crude OR Adjusted OR3 
OR (95% CI)2 P OR (95% CI)2 P OR (95% CI)2 P OR (95% CI)2 P 
Sex Male 12/120 
(10) 
1.0 (ref) 0.01 1.0 (ref) <0.01 5/130 (4) 1.0 (ref) 0.9 1.0 (ref) 0.9 
Female 3/151 (2) 0.2 (0.1-0.7) 0.2 (0.1-0.6) 6/171 (4) 0.9 (0.3-3.0) 1.0 (0.3-3.3) 
Current age 
group 
(years)4 
<30 3/43 (7) 1.0 (ref) 0.6 1.0 (ref) 0.9 3/46 (7) 1.0 (ref) 0.2 1.0 (ref) 0.2 
30 – 39 6/107 (6) 0.8 (0.2-2.9) 1.1 (0.3-4.8) 5/117 (4) 0.6 (0.1-2.8) 0.7 (0.1-3.0) 
40 – 49 3/50 (6) 0.9 (0.2-4.5) 1.1 (0.2-6.4) 1/57 (2) 0.3 (0.1-2.6) 0.3 (0.1-2.8) 
≥50 3/71 (4) 0.6 (0.1-2.9) 1.1 (0.2-6.2) 2/81 (2) 0.4 (0.1-2.3) 0.4 (0.1-2.2) 
Maternal 
HBsAg 
Negative 4/112 (4) 1.0 (ref) 0.01 1.0 (ref) <0.01 2/123 (2) 1.0 (ref) 0.03 1.0 (ref) 0.03 
Positive 9/61 (15) 4.7 (1.4-15.9) 5.0 (1.6-15.4) 6/66 (9) 6.1 (1.2-30.1) 5.5 (1.2-24.4) 
HBV 
genotype 
Genotype E 8/92 (9) 1.0 (ref) 0.02 1.0 (ref) 0.04 8/101 (8) 1.0 (ref) N/A 1.0 (ref) N/A 
Genotype A 2/3 (67) 21.0 (1.7-266.1) 20.7 (1.2-368.1) 0/5 (0) N/A N/A 
R249S 
mutation 
Negative 3/96 (3) 1.0 (ref) 0.06 1.0 (ref) 0.03 0/111 (0) 1.0 (ref) N/A 1.0 (ref) N/A 
Positive 9/79 (11) 4.0 (1.0-16.4) 5.1 (1.1-23.3) 8/86 (9) N/A N/A 
Persistence 
of HBeAg4 
Negative at 
baseline 
3/158 (2) 1.0 (ref) <0.01 1.0 (ref) <0.01 2/178 (1) 1.0 (ref) <0.01 1.0 (ref) <0.01 
Cleared 
during F/U 
8/101 (8) 4.4 (1.2-16.7) 12.0 (1.1-134.1) 5/109 (5) 4.2 (0.8-22.0) 9.4 (0.5-165.9) 
Still 
positive 
4/12 (33) 25.8 (5.4-123.8) 125.5 (9.5-
1650.9) 
4/14 (29) 35.2 (6.0-205.1) 111.9 (5.9-
2138.1) 
% samples 
with HBV 
DNA 
≥2,000 
Never 2/109 (2) 1.0 (ref) <0.01 1.0 (ref) 0.02 1/129 (1) 1.0 (ref) <0.01 1.0 (ref) <0.01 
<50% 5/83 (6) 3.4 (0.7-17.9) 4.9 (0.7-36.2) 1/88 (1) 1.4 (0.1-24.1) 3.2 (0.3-37.3) 
≥50% 8/48 (17) 10.7 (2.2-52.0) 15.5 (1.5-164.1) 9/53 (17) 26.2 (3.3-209.9) 123.9 (10.5-
1461.4) 
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IU/ml4,5 
% samples 
with ALT 
≥40 IU/L4,5 
Never 5/208 (2) 1.0 (ref) <0.01 1.0 (ref) <0.01 3/233 (1) 1.0 (ref) <0.01 1.0 (ref) <0.01 
<50% 3/14 (21) 11.1 (2.3-52.5) 7.7 (1.6-36.8) 2/14 (14) 12.8 (1.9-84.9) 13.6 (1.7-106.5) 
≥50% 5/20 (25) 13.5 (3.6-50.7) 17.2 (2.5-118.6) 5/23 (22) 21.3 (4.6-99.3) 27.6 (3.8-200.1) 
1 Excluding participants who did not have a liver biopsy and who had invalid measurements with transient elastography. 
2 p-value and 95% CI were obtained by Wald test with robust standard error to take account of clustering among individuals who share the same 
mother. 
3 OR adjusted for sex, current age and birthplace. 
4 Test for linear trend. 
5 This only includes subjects who had at least two measurements during the follow-up. 
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Population attributable fractions 
Maternal sero-status was recorded in 977 unvaccinated participants in Keneba/Manduar 
between 1974 and 2008, among whom 230 became chronic HBV carriers. The mother was 
HBsAg-positive in 32.2% of all the chronic carriers, 64.3% of carriers with significant 
fibrosis, and 71.4% of carriers requiring antiviral treatment according to the EASL guidelines. 
After controlling for age and sex, having an HBsAg-positive mother was associated with 
chronic carriage (OR: 2.0, 95% CI: 1.3-3.1), significant fibrosis (OR: 6.4, 2.1-19.8), and 
requiring antiviral treatment (OR: 8.5, 1.8-40.9). Consequently, the population attributable 
fraction, that is the proportion of chronic carriers attributable to having an HBsAg-positive 
mother was 16.0% (95% CI: 8.6-22.9%), and the population attributable fractions for HBV-
related significant fibrosis and cases requiring antiviral treatment were 54.3% (41.5-64.3%) 
and 63.0% (47.0-74.1%), respectively.    
 
DISCUSSION 
This is the first long-term follow-up of a population-based cohort of chronic HBV carriers in 
SSA [3,31,32]. We confirmed that the age-standardized rate of HCC in the chronic carriers in 
this study (67.3/100,000) was much higher than in the general population in The Gambia 
(22.1/100,000) [27], which highlights the importance of controlling chronic HBV infection to 
prevent HCC. Of note, only 3.7% and 1.7% of chronic carriers assessed in 2012-2013 met the 
EASL and WHO criteria for antiviral treatment, respectively, making HBV a tractable health 
problem. The PROLIFICA project, the first treatment program for HBV mono-infected 
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individuals in SSA, will assess the effectiveness of HBV screening and antiviral therapy in 
reducing HCC in The Gambia and Senegal.   
The incidence rate of HCC in adult men with chronic HBV infection differs considerably by 
geographical location: 34/100,000 carrier-years in Europe [33], 230/100,000 in Alaska [34], 
327/100,000 in New Zealand Maori [35] and 530-880/100,000 in East Asia [36,37]. In SSA, 
the recorded rates in adult male lie between Europe and Asia (68.3/100,000 in Senegalese 
army [36] and 183.5/100,000 in our population-based cohort). These variations in HCC 
incidence might be partly explained by a difference in the natural history of chronic HBV 
infection as is discussed below. 
It is well established that persistence of high HBV viral load [37,38] or HBeAg [39] increases 
the risk of HCC, and the current study also confirmed an elevated risk of significant fibrosis 
in carriers with these conditions. In contrast to East Asia where about half of carrier children 
remain HBeAg-positive into their twenties [40], in SSA, decay of viral replication occurs 
much faster. We found that half of chronic carriers lost HBeAg by the age of puberty, and 
amongst those who cleared, the majority became inactive carriers with low or undetectable 
HBV DNA, and few developed HCC or HBeAg-negative chronic hepatitis. 
Another question is what determines the difference in trajectory of viral replication between 
Asia and SSA. Evans et al. argued that the difference can be explained by the major mode of 
HBV transmission [36]: in East Asia 40% of chronic carriers were infected vertically 
compared with only 10% in SSA before the introduction of hepatitis B vaccine [6]. In our 
study we estimated that 16% of chronic infection attributable to mother-to-infant transmission. 
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We found that having an HBsAg-positive mother, which is a proxy for mother-to-infant 
transmission that occurs perinatally or during early childhood, was a risk factor for 
maintenance of viremia in The Gambia. Moreover, maternal HBsAg was also associated with 
high ALT, higher prevalence of significant fibrosis and treatment eligibility, and higher HCC 
incidence among chronic carriers. By restricting to chronic carriers, our analysis suggests that 
maternal transmission not only increases the risk of chronic infection [30] but may also 
further increase the risk of persistent viral replication and severe liver disease [8]. These 
findings are consistent with previous Asian studies that assessed the effect of maternal HBV 
status [7,8]. Persistent HBV replication may be facilitated in infants because they have an 
immature immune system [32]. 
In the pre-vaccine era, horizontal transmission during childhood was more common than 
perinatal maternal transmission in SSA, and our data support this (16.0% of chronic infection 
attributable to mother-to-infant transmission). However, we also found that only 3.7% of 
chronic carriers required antiviral therapy, and most of these cases (63.0%) were attributable 
to mother-to-infant transmission. This population attributable fraction may even be higher in 
the post-vaccine era, because the first dose of hepatitis B vaccine is usually delayed for more 
than one week and therefore perinatal maternal transmission is not well prevented in The 
Gambia [4,41,42]. Indeed, in our cohort, 60.9% of children who became chronic carriers 
despite having been fully vaccinated had HBsAg-positive mothers and none received the first 
vaccine at birth, implying that they were already infected from their mothers before the 
vaccination. 
These findings suggest the importance of interrupting mother-to-infant transmission to reduce 
the HBV-related disease burden in SSA. Although the WHO recommends a timely 
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administration of hepatitis B vaccine within 24 hours of birth to prevent perinatal and early 
horizontal transmission [3,5], only 11% of newborns currently receive a birth dose in SSA 
[43]. This is partly because birth dose is difficult to implement in population where many 
births take place at home, but also because the Global Alliance for Vaccines and 
Immunization (GAVI) only provides the pentavalent vaccine (DTP-HepB-Hib), which cannot 
be used at birth. The feasibility and cost-effectiveness of a timely birth dose vaccine or other 
strategy (e.g., antiviral therapy for infectious pregnant women) needs to be investigated in 
SSA [44]. 
The study is also the first longitudinal cohort to show the association between p53R249S, a 
marker of chronic aflatoxin exposure, and liver fibrosis. Moreover, we also found a 
differential risk in liver disease between genotypes A and E, although the number infected 
with genotype A was small. In West and Central Africa, genotype E is predominant followed 
by A, whereas in Asia genotype C is common [45]. The latter is associated with delayed 
HBeAg loss compared with genotypes A, B, D, and F [46], and this may explain why 
persistent viral replication is more common in East Asia than SSA. Unfortunately, a direct 
comparison of clinical outcomes between genotype C and E is difficult because their 
geographical distributions do not overlap. 
The American Guidelines for chronic HBV infection recommend starting the screening for 
HCC in African HBV carriers at an early age (≥20 years old) [26]. This is  based on several 
African case-series where a young median age at HCC diagnosis was reported [9,47]. 
However, of six HCC cases in this study only one (17%) was <40 years old. This needs to be 
further studied as this recommendation is costly. 
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Our study has several limitations. First, the interval between follow-up sero-surveys (4-5 
years) was longer than other longitudinal studies [34,35,48] which might have affected the 
estimates of HBeAg/HBsAg sero-clearance. Nonetheless, the rates are within a range that has 
been previously reported (HBeAg clearance: 6-9%/year, HBsAg clearance: 0.5-1.6%/year) 
[34,35,48]. Second, ideally, we would have used maternal HBeAg status at the birth of the 
child as a proxy for mother-to-infant transmission, since maternal HBeAg positivity is a 
stronger predictor of maternal transmission than HBsAg. However, maternal sero-status was 
determined when the child entered the cohort, and by this time maternal HBeAg is likely to 
have been lost [8]. Third, the phases of the natural history of chronic HBV infection might 
have been incorrectly classified as they were determined on a single assessment rather than 
longitudinal monitoring. Fourth, HBV DNA was measured in historical samples, and its 
levels might have been affected by a prolonged storage and multiple freeze-thaw cycles. 
Nevertheless, the effect of freeze-thaw cycles is reported to be minimal for HBV DNA assays 
[49]. Finally, the HCC cases were ascertained through linkage with the cancer registry 
database, which is estimated to record only 50% of cases [50]. We attempted to mitigate this 
bias by also reviewing medical records at the local clinic. 
In conclusion, compared to East Asia, the natural history of chronic HBV infection in West 
Africa is characterized by a shorter duration of viremia and lower incidence of HCC, which is 
probably due to the lower frequency of mother-to-infant transmission in SSA. Among those 
who develop severe liver disease in The Gambia the majority are infected by their mothers, 
emphasizing the importance of interrupting perinatal transmission in SSA. 
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FIGURE LEGENDS 
Figure 1. Flow diagram of study participants 
 
Figure 2. Proportion of chronic HBV carriers who cleared HBeAg and HBsAg as a function 
of age* 
 
* The number at risk is smaller at 5 and 15 years than at 25 years in the figure for HBsAg 
because the median age of recruitment was 10.8 years. 
 
Figure 3. Changes with age in serum HBV DNA (A) and ALT levels (B) by maternal HBsAg 
status (- and + denote negative and positive maternal HBsAg, respectively) amongst chronic 
HBV carriers*  
 
* Two outliers (ALT: 166 and 351 IU/L) in positive maternal HBsAg group are not presented 
in the figure 3-B.  
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Abstract  
Background 
The natural history of chronic hepatitis B virus (HBV) infection in sub-Saharan Africa is 
unknown. Data is required to inform WHO guidelines which are currently based on studies in 
Europe and Asia. 
Methods 
Between 1974 and 2008, sero-surveys were repeated in two Gambian villages, and an open 
cohort of treatment-naïve chronic HBV carriers was recruited. Participants were followed to 
estimate the rates of hepatitis B e (HBeAg) and surface antigen (HBsAg) clearance and 
incidence of hepatocellular carcinoma (HCC). In 2012-2013, a comprehensive liver 
assessment was conducted to estimate the prevalence of severe liver disease.  
Results 
405 chronic carriers (95% genotype E), recruited at a median age of 10.8 years, were followed 
for a median length of 28.4 years. Annually, 7.4% (95% CI: 6.3-8.8%) cleared HBeAg and 
1.0% (0.8-1.2%) cleared HBsAg. The incidence of HCC was 55.5/100,000 carrier-years (95% 
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CI: 24.9-123.5). In the 2012-2013 survey (n=301), 5.5% (95% CI: 3.4-9.0%) had significant 
liver fibrosis. HBV genotype A (versus E), chronic aflatoxin B1 exposure, and an HBsAg-
positive mother, a proxy for mother-to-infant transmission, were risk factors for liver fibrosis. 
A small proportion (16.0%) of chronic carriers were infected via mother-to-infant 
transmission, however, this population represented a large proportion (63.0%) of the cases 
requiring antiviral therapy.  
Conclusions 
The incidence of HCC amongst chronic HBV carriers in West Africa was higher than that in 
Europe but lower than rates in East Asia. High risk of severe liver disease amongst the few 
who are infected by their mothers underlines the importance of interrupting perinatal 
transmission in sub-Saharan Africa. 
  
Summary Box 
What is already known about this subject? 
- Chronic hepatitis B virus infection is a common cause of liver disease in sub-Saharan 
Africa. 
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8 
 
- Although the WHO recently published its first HBV treatment guidelines with a main 
focus on resource-limited countries, their recommendations are based on Western and 
Asian studies, since there have been no natural history data from sub-Saharan Africa. 
- Mother-to-infant transmission is a risk factor for chronic HBV infection, however, it is 
unclear whether this mode of transmission further increases the risk of severe liver 
disease in chronic carriers. 
What are the new findings? 
- The incidence rate of hepatocellular carcinoma (HCC) in treatment-naïve male chronic 
HBV carriers in The Gambia was higher than Europe but lower than in East Asia. 
- Mother-to-infant transmission was a risk factor for persistent viral replication, elevated 
transaminase, significant fibrosis and HCC. 
- The majority (63.0%) of cases requiring antiviral therapy were attributable to maternal 
transmission. 
- Among chronic HBV carriers, genotype A (versus E) and chronic exposure to 
aflatoxin B1 were associated with an elevated risk of significant liver fibrosis. 
How might it impact on clinical practice in foreseeable future? 
- The disproportionate risk of severe liver disease amongst people who acquired HBV 
from their mothers emphasizes the importance of interrupting perinatal transmission in 
sub-Saharan Africa. 
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INTRODUCTION 
In sub-Saharan Africa (SSA) chronic hepatitis B virus (HBV) infection is a major public 
health problem, which causes an estimated 61,000 deaths due to cirrhosis or hepatocellular 
carcinoma (HCC) each year [1]. Before the introduction of hepatitis B vaccine, >70% of 
African children were exposed to HBV at birth or during childhood and 10-20% became 
chronic HBV carriers [2]. Currently, all African countries have integrated hepatitis B vaccine 
into their Expanded Program on Immunization (EPI).  
Despite its efficacy in preventing chronic HBV infection, vaccination has several limitations 
as a control strategy. First, a large number of people who were infected prior to the 
vaccination programs are left with chronic HBV infection [3]. Second, hepatitis B vaccine 
does not always prevent mother-to-infant transmission [4], especially when the vaccine is not 
given at birth [5]. Though this mode of transmission is less frequent than horizontal 
transmission in SSA [6], the risk of HCC may be higher in vertically-transmitted chronic 
infections [7–9]. 
To overcome these limitations, antiviral therapy can be used to prevent HBV-related disease 
in cases of chronic HBV infection and also to prevent vertical HBV transmission. In March 
2015, the World Health Organization (WHO) issued its first guidelines on chronic HBV 
infection to improve access to antiviral therapy in low- and middle-income countries. 
However, their recommendations are based on the findings from Asia, Europe and North 
America, since there have been no natural history data from SSA [3]. Understanding the 
natural history of chronic HBV infection is essential to inform decisions about who to treat 
and when to treat [3]. 
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10 
 
The UK Medical Research Council (MRC), the International Agency for Research on Cancer 
(IARC/WHO) and the Gambia Government have been supporting studies on HBV infection 
in The Gambia since the 1980’s, and have established a population-based open cohort of 
treatment-naïve chronic HBV carriers. We used this cohort to describe the natural history of 
chronic HBV infection: i) the sero-clearance rates of hepatitis B e antigen (HBeAg) and 
surface antigen (HBsAg); ii) the incidence of HCC, end-stage liver disease (ESLD) and all-
cause mortality; iii) longitudinal changes in serum HBV DNA and alanine transaminase (ALT) 
levels; and iv) the prevalence of significant liver fibrosis and chronic liver disease requiring 
antiviral therapy according to the European Association for the Study of the Liver (EASL) [10] 
or the WHO guidelines [3]. We also estimated the HBV-related disease burden attributable to 
the mother-to-infant transmission in SSA by examining the associations between these 
outcomes and maternal HBsAg, a proxy for mother-to-infant HBV transmission [8].  
 
METHODS 
Participants 
The cohort of chronic HBV carriers was recruited from Keneba and Manduar, two 
neighboring villages in West Kiang District. They are typical of many African rural 
communities where Mandinka and Jola people live in mud or lath-and-plaster houses roofed 
with thatch or corrugated iron with subsistence agriculture [11]. Primary health care has been 
available free of charge at the MRC Keneba Clinic. Baseline HBV sero-surveys were 
undertaken in 1974 and in 1980. In the first survey the entire population was surveyed 
(n=1,317) and 13.2% were found to carry HBsAg [11] while the second survey was limited to 
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11 
 
children aged <15 years and their mothers (n=802) [12]. Following the third sero-survey in 
1984 [13], all non-immune children in Keneba/Manduar were invited to participate in an 
HBV vaccine trial [14]. Hepatitis B vaccination was introduced in the EPI in 1990 with a 
vaccine schedule starting at birth. Hepatitis B immunoglobulin has been unavailable. Between 
1985 and 2008, sero-surveys to measure the vaccine efficacy were repeated every 4-5 years 
[4,14–17]. In parallel, those who had been tested HBsAg-positive were followed for HBV 
sero-markers in 1985, 1989, 1992, 1993, 1998, 2003, and 2008 (supplementary table 1). 
Survey participation was 92-100% and 50-85% in those aged 0-9 and 10-19 years, 
respectively [12–15].   
Liver assessment in 2012-2013 
Following community approval, people with chronic HBV infection in the cohort were invited 
to a liver assessment as part of the PROLIFICA (Prevention of Liver Fibrosis and Cancer in 
Africa) project [18]. Chronic infection was defined as serum HBsAg positivity at two visits at 
least six months apart. In individuals aged ≥13 years, HBsAg positivity at only one visit was 
considered as chronic infection because, in the pre-vaccination era, 90% of children in 
Keneba/Manduar acquired the infection by the age of 13 years and new infections were 
uncommon beyond this age [13]. After written informed consent, participants, who had fasted 
overnight, underwent a standardized clinical examination that involved blood collection, 
abdominal ultrasound and liver stiffness measurement using transient elastography (Fibroscan, 
Echosens, France). Those with serum HBV DNA ≥2,000 IU/ml or liver stiffness ≥6.5 kPa or 
ALT ≥40 IU/L, were invited for liver biopsy. Histopathologists in UK scored liver fibrosis 
using Metavir system [19]. The study was approved by the Gambia Government/MRC Joint 
Ethics Committee and conducted according to the guidelines of the Declaration of Helsinki. 
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Laboratory assays 
HBsAg was detected by radioimmunoassay (Ausria-I, Abbott, USA) in 1974 [12], reverse 
passive hemagglutination assay (Wellcotest, Wellcome Diagnostics, UK) in 1980-1998 [15], 
immunochromatography (Determine, Abbott) in 2003-2008 [20], and chemiluminescent 
microparticle immunoassay (Architect, Abbott) in 2012-2013 [21]. HBsAg-positive samples 
were tested for HBeAg by radioimmunoassay in 1980-1998 [15] and later by enzyme 
immunoassay (EIA) (Diasorin, Biomedica, Italy) [20]. The serological tests were strongly 
correlated with one another [20,21]. HBV DNA levels were measured at the end of the study 
in stored samples collected in 1984, 1989, 1993, 2003, 2008, and 2012-2013, using in-house 
quantitative real-time polymerase chain reaction (detection limit: 50 IU/ml), calibrated against 
an international standard [22]. As previously reported, samples collected in 2003 were 
examined for HBV genotype and an AGG→AGT mutation at codon 249 of p53 tumor 
suppressor gene (p53R249S) in cell-free DNA, a biomarker of chronic aflatoxin B1 exposure 
[23]. Samples collected in 2012-2013 were tested for alpha-fetoprotein and antibodies to 
Hepatitis C virus (HCV) using microparticle EIA (AxSYM, Abbott), antibodies to Hepatitis D 
virus (HDV) using EIA (ETI-AB-DELTAK-2, Diasorin), and antibodies to HIV-1/2 and p24 
antigen using EIA (Genscreen-ULTRA, Bio-Rad, USA). Schistosoma mansoni infection is 
rare in The Gambia [24] and therefore was not investigated.  
Ascertainment of liver disease and death 
Significant liver fibrosis, severe fibrosis and cirrhosis was defined as ≥F2, ≥F3 and F4 
(Metavir) for those who had liver histopathology and liver stiffness ≥7.9, ≥8.2 and ≥9.5 kPa 
for those without biopsy. These cut-offs were determined by our validation study in The 
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Gambia, where the sensitivity of Fibroscan to predict ≥F2 was 81% and the specificity was 81% 
[25]. The EASL criteria for antiviral therapy are: i) viral load ≥2,000 IU/ml and significant 
fibrosis, or  ii) viral load ≥2,000 IU/ml and moderate/severe active necroinflammation (≥A2 
by Metavir activity grade), or iii) viral load ≥20,000 IU/ml and ALT ≥80 IU/L, or iv) 
detectable viral load and cirrhosis [10]. The WHO criteria are: i) clinically diagnosed cirrhosis, 
or ii) aspartate transaminase (AST)-to-platelet ratio index (APRI) >2.0, or iii) ≥30 years old 
and abnormal ALT and HBV DNA >20,000 IU/ml [3]. The phases of the natural history of 
chronic HBV infection were described [10,26] for the baseline and 2012-2013 survey 
(supplementary table 2). 
HCC cases were identified through a follow-up examination, review of medical records in the 
MRC Keneba Clinic, or by data linkage with the Gambia National Cancer Registry [27]. The 
diagnosis was based on the identification of a focal hepatic lesion consistent with HCC on the 
ultrasound and elevated serum alpha-fetoprotein (≥200 ng/ml). ESLD includes HCC and non-
malignant ESLD. The latter was defined as cirrhosis without HCC and the presence of ascites, 
hepatic encephalopathy, or hematemesis. The date of death was ascertained through a review 
of the medical chart in the MRC or data linkage with the West Kiang Demographic 
Surveillance System [28].  
Statistical analyses  
The person-years of follow-up for HBeAg/HBsAg clearance, HCC, ESLD, or death were 
calculated from the date they were identified as HBsAg-positive to the date of endpoint or last 
follow-up, whichever came first. The date of sero-clearance was defined as the midpoint 
between the last positive and the first negative result. The cumulative incidence was estimated 
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as a function of age using the Kaplan-Meier Method. Age was used rather than time since 
entry into the study because most infections occur during early childhood [13], and therefore 
age approximates the duration of HBV infection. The associations between maternal HBsAg, 
as recorded at the recruitment of the child, and the HBeAg/HBsAg loss were examined using 
Poisso  regression with robust standard error to account for clustering in children that share 
the same mother. The models included current age, calendar year, sex, and birthplace as 
covariates. The effect of maternal HBsAg on ALT and HBV DNA (log10 transformed) was 
quantified using a linear mixed model with random intercept and random slope to account for 
the multiple measurements made on the same individuals over time. The detection limit of the 
assay was assigned to samples with undetectable viral load. The effect of maternal HBsAg on 
significant fibrosis and meeting antiviral treatment criteria was estimated using logistic 
regression to control for age, sex, and birthplace (partial model), and additionally for HBV 
genotype and p53R249S (full model). 
Population attributable fractions were calculated [29] for the effects of maternal sero-status on 
chronic HBV infection and HBV-related liver disease (significant fibrosis and meeting the 
EASL treatment criteria). This analysis included all the survey participants (1974-2008) with 
available maternal sero-status who did not receive hepatitis B vaccine. It was not restricted to 
chronic carriers so that the twofold effect of mother-to-infant transmission could be estimated, 
i.e., the increased risk of both chronic infection [30], and of liver disease progression in those 
with established chronic infection [8,9]. All analyses were performed using STATA 11.0 
(Stata Corporation, USA). 
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RESULTS 
Baseline characteristics 
Between 1974 and 2008, 551 villagers tested positive for HBsAg at least once in the 
Keneba/Manduar sero-surveys. None had HCC at enrolment. Twenty-nine HBsAg-positive 
villagers did not participate in any subsequent sero-surveys. These individuals did not differ 
from the rest of HBsAg-positive individuals in sex, age, HBeAg, HBV DNA and ALT levels 
at baseline. Finally, there were 405 chronic carriers (figure 1). The median length of follow-
up was 28.4 years (IQR: 17.7-32.7) with the median number of six sero-surveys (IQR: 3-8). 
The median age at recruitment was 10.8 years (IQR: 4.6-21.8). Half were male, and 65.2%, 
26.1%, and 8.7% had a mother who was HBsAg-negative, HBsAg-positive/HBeAg-negative, 
and HBsAg-positive/HBeAg-positive, respectively (table 1). The children of positive mothers 
had high viral load (p=0.04) and abnormal ALT levels (p=0.05) at baseline. Thirty became 
chronic carriers despite having been fully vaccinated against HBV; median age at the first 
vaccine was 34 days and none received within three days of birth, and the majority (60.9%, 
14/23) had HBsAg-positive mothers. In the 2003 sero-survey, 95.1% (97/102) had genotype E 
and the rest genotype A; 44.2% (100/226) had the p53R249S mutation [23].  
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Table 1. Baseline characteristics of people with chronic HBV infection by maternal HBsAg 
status (N=405) 
Variables All (N=405) Unknown 
maternal 
sero-status 
(n=152) 
With 
HBsAg(+) 
mother 
(n=88) 
With 
HBsAg(-) 
mother 
(n=165) 
p-
value1 
 
Sex Male 204 (50%) 63 (41%) 48 (55%) 93 (56%) 0.8 
Female 201 (50%) 89 (59%) 40 (45%) 72 (44%)  
Age group 
(years) 
<5 109 (27%) 4 (3%) 42 (48%) 63 (38%) 0.92 
5 – 9 83 (20%) 9 (6%) 22 (25%) 52 (32%)  
10 – 14 56 (14%) 16 (10%) 8 (9%) 32 (19%)  
15 – 19 39 (10%) 23 (15%) 5 (6%) 11 (7%)  
≥20 118 (29%) 100 (66%) 11 (12%) 7 (4%)  
Birth place Keneba 233 (58%) 106 (70%) 39 (44%) 88 (53%) 0.4 
Manduar 172 (42%) 46 (30%) 49 (56%) 77 (47%)  
Hepatitis 
B vaccine 
Never 375 (93%) 145 (95%) 74 (84%) 156 (95%) 0.02 
Ever 30 (7%) 7 (5%) 14 (16%) 9 (5%)  
HBeAg Negative 213 (55%) 118 (86%) 30 (34%) 65 (40%) 0.4 
Positive 173 (45%) 19 (14%) 58 (66%) 96 (60%)  
HBV 
DNA 
(IU/ml) 
<2,000 222 (57%) 121 (83%) 30 (35%) 71 (45%) 0.042 
2,000-108 90 (23%) 20 (14%) 19 (22%) 51 (32%)  
≥108 79 (20%) 5 (3%) 37 (43%) 37 (23%)  
ALT 
(IU/L) 
<40 367 (94%) 134 (92%) 77 (91%) 156 (97%) 0.05 
≥40 25 (6%) 12 (8%) 8 (9%) 5 (3%)  
Phase of 
natural 
history 
Immune 
tolerant 
116 (29%) 8 (5%) 42 (48%) 66 (40%) 0.1 
HBeAg(+) 
chronic 
hepatitis 
14 (3%) 5 (3%) 7 (8%) 2 (1%)  
HBeAg(-) 
chronic 
hepatitis 
11 (3%) 7 (5%) 1 (1%) 3 (2%)  
Inactive carrier 190 (47%) 117 (77%) 22 (25%) 51 (31%)  
Unclassified 74 (18%) 15 (10%) 16 (18%) 43 (26%)  
HBV 
genotype3 
Genotype A 5 (5%) 1 (3%) 2 (8%) 2 (5%) 0.6 
Genotype E 97 (95%) 33 (97%) 24 (92%) 40 (95%)  
p53R249S 
mutation3 
Negative 126 (56%) 50 (63%) 23 (44%) 53 (56%) 0.1 
Positive 100 (44%) 30 (37%) 29 (56%) 41 (44%)  
Median no. of follow-up 
sero-surveys (IQR) 
6 (3, 8) 4 (3, 6) 6 (4, 8) 7 (5, 8) 0.1 
Median years of follow-up 
(IQR) 
28.4 (17.7, 
32.7) 
24.4 (10.2, 
37.9) 
28.6 (16.0, 
32.0) 
28.7 (23.8, 
32.1) 
0.2 
1 Comparison was made between participants with HBsAg-positive mothers and HBsAg-
negative mothers. P-value and 95% CI were obtained by Wald test with robust standard error. 
2 Linear test for trend 
3 Determined in a subset of participants in 2003 
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HBeAg sero-clearance 
At the enrolment, 213 (52.6%) chronic carriers had already lost HBeAg, The age-specific 
prevalence of HBeAg at baseline decreased with increasing age (supplementary figure 1). Of 
the 173 HBeAg-positive carriers at baseline, 82.1% lost HBeAg and the clearance rate was 
7.4%/year (95% CI: 6.3-8.8) (table 2, figure 2). Fifteen experienced HBeAg reversion, nine of 
whom eventually lost HBeAg whilst six continued to carry HBeAg until the last follow-up. 
After adjusting for sex, current age, calendar year and birthplace, the sero-clearance rate was 
slower in carriers with high HBV DNA levels (≥108 IU/ml) at baseline (supplementary table 
3). Carriers with HBsAg-positive mothers tend to clear HBeAg slowly, although this did not 
reach statistical significance (supp ementary figure 2-A).  
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Table 2. Incidence rates of HBeAg and HBsAg sero-clearance, HCC, ESLD and all-cause 
mortality in people with chronic HBV infection by gender 
Event No. of 
subjects 
Person-years 
at risk 
No. of 
events 
Rate 95% CI 
HBeAg clearance 173 1912 142 7.4 / 100  6.3 – 8.8 
  Male   109   1231   86   7.0   5.7 – 8.6 
  Female   64   681   56   8.2   6.3 – 10.7 
HBsAg clearance 405 8502 85 1.00 / 100  0.81 – 1.24 
  Male   204   4076   32   0.79   0.56 – 1.11 
  Female   201   4426   53   1.20   0.91 – 1.57 
HCC 405 10815 6 55.5 / 100,000  24.9 – 123.5 
  Male   204   5200   6   115.4   51.8 – 256.8 
   Boys (<20 y.o.)   1930  0  0.0  N/A 
   Adult men (≥20 y.o.)   3270  6  183.5  82.4 – 408.5 
  Female   201   5615   0   0.0   N/A 
ESLD (including HCC) 405 10815 8 74.0 / 100,000 37.0 – 147.9 
  Male   204   5200   7   134.6   64.2 – 282.4 
  Female   201   5615   1   17.8   2.5 – 126.4 
All-cause mortality 405 10815 43 397.6 / 100,000  294.9 – 536.1 
  Male   204   5200   25   480.8   324.9 – 711.5 
  Female   201   5615   18   320.6   202.0 – 508.8 
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HBsAg sero-clearance 
The rate of HBsAg sero-clearance was 1.0%/year (95% CI: 0.8-1.2) (table 2) with half 
clearing by 57 years old (figure 2). Younger age and high HBV DNA levels at baseline were 
associated with delayed HBsAg sero-clearance (supplementary table 4). The sero-clearance 
rate was slower in carriers with HbsAg-positive mothers, but this was not statistically 
significant (supplementary figure 2-B). 
HCC, ESLD, and mortality 
Of the 405 chronic carriers, 43 died; the all-cause mortality rate was 397.6/100,000 person-
years (95% CI: 294.9-536.1). The most common cause of death was HCC (24.0%) in men and 
bacterial infection (22.2%) in women. All patients with ESLD (including HCC (n=6) and 
non-malignant ESLD (n=2)) died within one year of diagnosis. Incidence rates of HCC and 
ESLD were 55.5 (95% CI: 24.9-123.5) and 74.0 (95% CI: 37.0-147.9) per 100,000 person-
years, respectively (table 2). All HCC patients were men, all but one was HBeAg-negative at 
enrolment, and their age at diagnosis ranged between 38 and 67 years (supplementary table 5). 
The HCC incidence in men ≥20 years was 183.5 (95% CI: 82.4-408.5) per 100,000 person-
years. Maternal sero-status was available in three ESLD patients, and all had HBsAg-positive 
mothers. Crude incidence rates of HCC in carriers with HBsAg-positive mothers was 
89.2/100,000 (95% CI: 22.3-356.8) while those with negative mothers was 0/100,000 
(unadjusted p<0.001). 
Mean HBV DNA and ALT over time 
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The trajectories of HBV DNA and ALT levels by maternal HBsAg are presented in figure 3. 
Viral load decreased with increasing age at measurement whilst ALT increased. Both viral 
load and ALT were higher in men than women (supplementary table 6). After adjusting for 
confounders, the geometric mean viral load was 4.7 times higher (95% CI: 2.0-11.1, p<0.001) 
and mean ALT was 4.0 IU/L higher (95% CI: 1.2-6.8, p=0.005) in carriers with HBsAg-
positive mothers than in those with HBsAg-negative mothers.  
Prevalence of chronic liver disease in 2012-2013 
After excluding those who died, 83.1% (301/362) of chronic HBV carriers participated in the 
liver assessment in 2012-2013 (figure 1). Participation was lower in men than women, in 
younger than in older age groups and in carriers with positive HBeAg at baseline compared 
with those HBeAg-negative. Table 3 presents the characteristics of the participants. None had 
ever received antiviral or immunosuppressive therapy. The number co-infected with HIV, 
HCV, and HDV was three, one, and one, respectively. None had alcohol intake >20 g/day 
based on the standardized questionnaire. Between the baseline and 2012-2013 survey, the 
proportion of carriers in the immune tolerant phase decreased from 28.6% to 2.3% whilst the 
proportion in the inactive phase increased from 46.9% to 64.5% (tables 1 and 3, 
supplementary figure 3). Only 6.3% were in HBeAg-negative chronic hepatitis in 2012-2013. 
Thirty participants had a liver biopsy and 269 had a valid measurement using transient 
elastography. No liver specimen had steatosis. Fifteen carriers (5.5%, 95% CI: 3.4-9.0%) had 
significant fibrosis, including nine with severe fibrosis and one with cirrhosis. After 
controlling for confounders, male gender, genotype A, p53R249S mutation, persistence of 
HBeAg, high viral load, and ALT were risk factors for significant fibrosis (table 4). After 
adjusting for sex, age, birthplace, HBV genotype and p53R249S, the odds ratio (OR) for the 
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effect of maternal HBsAg on significant fibrosis was 15.8 (95% CI: 1.4-174.1, p=0.02). 
Eleven participants (3.7%, 95% CI: 2.0-6.5%) met the EASL treatment criteria. Carriers with 
an HBsAg-positive mother, HBeAg persistence, frequent high viral load, and abnormal ALT 
were more likely to require antiviral therapy (table 4). Only five participants (1.7%, 95% CI: 
0.7-3.9%) fulfilled the WHO treatment criteria. 
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Table 3. Characteristics of people with chronic HBV infection who participated in the liver 
assessment 2012-2013 by maternal HBsAg status (N=301) 
Variables All (N=301) With HBsAg(+) 
mother (n=66) 
With HBsAg(-) 
mother (n=123) 
p-
value1 
Sex Male 130 (43%) 32 (48%) 59 (48%) 0.9 
Female 171 (57%) 34 (52%) 64 (52%)  
Current 
age group 
(years) 
<30 46 (15%) 17 (26%) 18 (14%) 0.82 
30 – 39 117 (39%) 30 (45%) 66 (54%)  
40 – 49 57 (19%) 8 (12%) 28 (23%)  
≥50 81 (27%) 11 (17%) 11 (9%)  
Birth 
place 
Keneba 178 (59%) 27 (41%) 65 (53%) 0.3 
Manduar 123 (41%) 39 (59%) 58 (47%)  
ALT in 
2012/2013 
<40 IU/L 268 (91%) 54 (84%) 110 (93%) 0.08 
≥40 IU/L 25 (9%) 10 (16%) 8 (7%)  
HBV 
marker in 
2012/2013 
HBsAg(+), HBeAg(+) 14 (5%) 6 (9%) 6 (5%) 0.32 
HBsAg(+), HBeAg(-) 227 (75%) 53 (80%) 100 (81%)  
HBsAg(-) 60 (20%) 7 (11%) 17 (14%)  
HBV 
DNA 
(IU/ml) in 
2012/2013 
Undetectable 135 (47%) 23 (35%) 59 (50%) 0.022 
50-200 65 (22%) 16 (24%) 26 (22%)  
200-2,000 57 (20%) 13 (20%) 23 (19%)  
2,000-20,000 11 (4%) 4 (6%) 4 (3%)  
≥20,000 20 (7%) 10 (15%) 7 (6%)  
Phase of 
natural 
history in 
2012/2013 
Immune tolerant 7 (2%) 2 (3%) 4 (3%) 0.8 
HBeAg(+) chronic 
hepatitis 
4 (1%) 4 (6%) 0 (0%)  
HBeAg(-) chronic 
hepatitis 
19 (6%) 6 (9%) 7 (6%)  
Inactive carrier 194 (65%) 41 (62%) 88 (71%)  
Occult HBV 12 (4%) 2 (3%) 5 (4%)  
Resolved hepatitis B 48 (16%) 5 (8%) 12 (10%)  
Unclassified 17 (6%) 6 (9%) 7 (6%)  
1 p-value from Wald test with robust standard error to take account of clustering among 
individuals who share the same mother. 
2 Linear test for trend 
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Table 4. Factors associated with significant liver fibrosis (n=271)1 and condition fulfilling the EASL treatment criteria (n=301) among people 
with chronic HBV infection who participated in the liver assessment 2012-13 
Variables Significant liver fibrosis (n=271) Meeting the EASL treatment criteria (n=301) 
Proportion 
(%) 
Crude OR Adjusted OR3 Proportion 
(%)  
Crude OR Adjusted OR3 
OR (95% CI)2 P OR (95% CI)2 P OR (95% CI)2 P OR (95% CI)2 P 
Sex Male 12/120 
(10) 
1.0 (ref) 0.01 1.0 (ref) <0.01 5/130 (4) 1.0 (ref) 0.9 1.0 (ref) 0.9 
Female 3/151 (2) 0.2 (0.1-0.7) 0.2 (0.1-0.6) 6/171 (4) 0.9 (0.3-3.0) 1.0 (0.3-3.3) 
Current age 
group 
(years)4 
<30 3/43 (7) 1.0 (ref) 0.6 1.0 (ref) 0.9 3/46 (7) 1.0 (ref) 0.2 1.0 (ref) 0.2 
30 – 39 6/107 (6) 0.8 (0.2-2.9) 1.1 (0.3-4.8) 5/117 (4) 0.6 (0.1-2.8) 0.7 (0.1-3.0) 
40 – 49 3/50 (6) 0.9 (0.2-4.5) 1.1 (0.2-6.4) 1/57 (2) 0.3 (0.1-2.6) 0.3 (0.1-2.8) 
≥50 3/71 (4) 0.6 (0.1-2.9) 1.1 (0.2-6.2) 2/81 (2) 0.4 (0.1-2.3) 0.4 (0.1-2.2) 
Maternal 
HBsAg 
Negative 4/112 (4) 1.0 (ref) 0.01 1.0 (ref) <0.01 2/123 (2) 1.0 (ref) 0.03 1.0 (ref) 0.03 
Positive 9/61 (15) 4.7 (1.4-15.9) 5.0 (1.6-15.4) 6/66 (9) 6.1 (1.2-30.1) 5.5 (1.2-24.4) 
HBV 
genotype 
Genotype E 8/92 (9) 1.0 (ref) 0.02 1.0 (ref) 0.04 8/101 (8) 1.0 (ref) N/A 1.0 (ref) N/A 
Genotype A 2/3 (67) 21.0 (1.7-266.1) 20.7 (1.2-368.1) 0/5 (0) N/A N/A 
R249S 
mutation 
Negative 3/96 (3) 1.0 (ref) 0.06 1.0 (ref) 0.03 0/111 (0) 1.0 (ref) N/A 1.0 (ref) N/A 
Positive 9/79 (11) 4.0 (1.0-16.4) 5.1 (1.1-23.3) 8/86 (9) N/A N/A 
Persistence 
of HBeAg4 
Negative at 
baseline 
3/158 (2) 1.0 (ref) <0.01 1.0 (ref) <0.01 2/178 (1) 1.0 (ref) <0.01 1.0 (ref) <0.01 
Cleared 
during F/U 
8/101 (8) 4.4 (1.2-16.7) 12.0 (1.1-134.1) 5/109 (5) 4.2 (0.8-22.0) 9.4 (0.5-165.9) 
Still 
positive 
4/12 (33) 25.8 (5.4-123.8) 125.5 (9.5-
1650.9) 
4/14 (29) 35.2 (6.0-205.1) 111.9 (5.9-
2138.1) 
% samples 
with HBV 
DNA 
≥2,000 
Never 2/109 (2) 1.0 (ref) <0.01 1.0 (ref) 0.02 1/129 (1) 1.0 (ref) <0.01 1.0 (ref) <0.01 
<50% 5/83 (6) 3.4 (0.7-17.9) 4.9 (0.7-36.2) 1/88 (1) 1.4 (0.1-24.1) 3.2 (0.3-37.3) 
≥50% 8/48 (17) 10.7 (2.2-52.0) 15.5 (1.5-164.1) 9/53 (17) 26.2 (3.3-209.9) 123.9 (10.5-
1461.4) 
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IU/ml4,5 
% samples 
with ALT 
≥40 IU/L4,5 
Never 5/208 (2) 1.0 (ref) <0.01 1.0 (ref) <0.01 3/233 (1) 1.0 (ref) <0.01 1.0 (ref) <0.01 
<50% 3/14 (21) 11.1 (2.3-52.5) 7.7 (1.6-36.8) 2/14 (14) 12.8 (1.9-84.9) 13.6 (1.7-106.5) 
≥50% 5/20 (25) 13.5 (3.6-50.7) 17.2 (2.5-118.6) 5/23 (22) 21.3 (4.6-99.3) 27.6 (3.8-200.1) 
1 Excluding participants who did not have a liver biopsy and who had invalid measurements with transient elastography. 
2 p-value and 95% CI were obtained by Wald test with robust standard error to take account of clustering among individuals who share the same 
mother. 
3 OR adjusted for sex, current age and birthplace. 
4 Test for linear trend. 
5 This only includes subjects who had at least two measurements during the follow-up. 
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Population attributable fractions 
Maternal sero-status was recorded in 977 unvaccinated participants in Keneba/Manduar 
between 1974 and 2008, among whom 230 became chronic HBV carriers. The mother was 
HBsAg-positive in 32.2% of all the chronic carriers, 64.3% of carriers with significant 
fibrosis, and 71.4% of carriers requiring antiviral treatment according to the EASL guidelines. 
After controlling for age and sex, having an HBsAg-positive mother was associated with 
chronic carriage (OR: 2.0, 95% CI: 1.3-3.1), significant fibrosis (OR: 6.4, 2.1-19.8), and 
requiring antiviral treatment (OR: 8.5, 1.8-40.9). Consequently, the population attributable 
fraction, that is the proportion of chronic carriers attributable to having an HBsAg-positive 
mother was 16.0% (95% CI: 8.6-22.9%), and the population attributable fractions for HBV-
related significant fibrosis and cases requiring antiviral treatment were 54.3% (41.5-64.3%) 
and 63.0% (47.0-74.1%), respectively.    
 
DISCUSSION 
This is the first long-term follow-up of a population-based cohort of chronic HBV carriers in 
SSA [3,31,32]. We confirmed that the age-standardized rate of HCC in the chronic carriers in 
this study (67.3/100,000) was much higher than in the general population in The Gambia 
(22.1/100,000) [27], which highlights the importance of controlling chronic HBV infection to 
prevent HCC. Of note, only 3.7% and 1.7% of chronic carriers assessed in 2012-2013 met the 
EASL and WHO criteria for antiviral treatment, respectively, making HBV a tractable health 
problem. The PROLIFICA project, the first treatment program for HBV mono-infected 
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individuals in SSA, will assess the effectiveness of HBV screening and antiviral therapy in 
reducing HCC in The Gambia and Senegal.   
The incidence rate of HCC in adult men with chronic HBV infection differs considerably by 
geographical location: 34/100,000 carrier-years in Europe [33], 230/100,000 in Alaska [34], 
327/100,000 in New Zealand Maori [35] and 530-880/100,000 in East Asia [36,37]. In SSA, 
the recorded rates in adult male lie between Europe and Asia (68.3/100,000 in Senegalese 
army [36] and 183.5/100,000 in our population-based cohort). These variations in HCC 
incidence might be partly explained by a difference in the natural history of chronic HBV 
infection as is discussed below. 
It is well established that persistence of high HBV viral load [37,38] or HBeAg [39] increases 
the risk of HCC, and the current study also confirmed an elevated risk of significant fibrosis 
in carriers with these conditions. In contrast to East Asia where about half of carrier children 
remain HBeAg-positive into their twenties [40], in SSA, decay of viral replication occurs 
much faster. We found that half of chronic carriers lost HBeAg by the age of puberty, and 
amongst those who cleared, the majority became inactive carriers with low or undetectable 
HBV DNA, and few developed HCC or HBeAg-negative chronic hepatitis. 
Another question is what determines the difference in trajectory of viral replication between 
Asia and SSA. Evans et al. argued that the difference can be explained by the major mode of 
HBV transmission [36]: in East Asia 40% of chronic carriers were infected vertically 
compared with only 10% in SSA before the introduction of hepatitis B vaccine [6]. In our 
study we estimated that 16% of chronic infection attributable to mother-to-infant transmission. 
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We found that having an HBsAg-positive mother, which is a proxy for mother-to-infant 
transmission that occurs perinatally or during early childhood, was a risk factor for 
maintenance of viremia in The Gambia. Moreover, maternal HBsAg was also associated with 
high ALT, higher prevalence of significant fibrosis and treatment eligibility, and higher HCC 
incidence among chronic carriers. By restricting to chronic carriers, our analysis suggests that 
maternal transmission not only increases the risk of chronic infection [30] but may also 
further increase the risk of persistent viral replication and severe liver disease [8]. These 
findings are consistent with previous Asian studies that assessed the effect of maternal HBV 
status [7,8]. Persistent HBV replication may be facilitated in infants because they have an 
immature immune system [32]. 
In the pre-vaccine era, horizontal transmission during childhood was more common than 
perinatal maternal transmission in SSA, and our data support this (16.0% of chronic infection 
attributable to mother-to-infant transmission). However, we also found that only 3.7% of 
chronic carriers required antiviral therapy, and most of these cases (63.0%) were attributable 
to mother-to-infant transmission. This population attributable fraction may even be higher in 
the post-vaccine era, because the first dose of hepatitis B vaccine is usually delayed for more 
than one week and therefore perinatal maternal transmission is not well prevented in The 
Gambia [4,41,42]. Indeed, in our cohort, 60.9% of children who became chronic carriers 
despite having been fully vaccinated had HBsAg-positive mothers and none received the first 
vaccine at birth, implying that they were already infected from their mothers before the 
vaccination. 
These findings suggest the importance of interrupting mother-to-infant transmission to reduce 
the HBV-related disease burden in SSA. Although the WHO recommends a timely 
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administration of hepatitis B vaccine within 24 hours of birth to prevent perinatal and early 
horizontal transmission [3,5], only 11% of newborns currently receive a birth dose in SSA 
[43]. This is partly because birth dose is difficult to implement in population where many 
births take place at home, but also because the Global Alliance for Vaccines and 
Immunization (GAVI) only provides the pentavalent vaccine (DTP-HepB-Hib), which cannot 
be used at birth. The feasibility and cost-effectiveness of a timely birth dose vaccine or other 
strategy (e.g., antiviral therapy for infectious pregnant women) needs to be investigated in 
SSA [44]. 
The study is also the first longitudinal cohort to show the association between p53R249S, a 
marker of chronic aflatoxin exposure, and liver fibrosis. Moreover, we also found a 
differential risk in liver disease between genotypes A and E, although the number infected 
with genotype A was small. In West and Central Africa, genotype E is predominant followed 
by A, whereas in Asia genotype C is common [45]. The latter is associated with delayed 
HBeAg loss compared with genotypes A, B, D, and F [46], and this may explain why 
persistent viral replication is more common in East Asia than SSA. Unfortunately, a direct 
comparison of clinical outcomes between genotype C and E is difficult because their 
geographical distributions do not overlap. 
The American Guidelines for chronic HBV infection recommend starting the screening for 
HCC in African HBV carriers at an early age (≥20 years old) [26]. This is  based on several 
African case-series where a young median age at HCC diagnosis was reported [9,47]. 
However, of six HCC cases in this study only one (17%) was <40 years old. This needs to be 
further studied as this recommendation is costly. 
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Our study has several limitations. First, the interval between follow-up sero-surveys (4-5 
years) was longer than other longitudinal studies [34,35,48] which might have affected the 
estimates of HBeAg/HBsAg sero-clearance. Nonetheless, the rates are within a range that has 
been previously reported (HBeAg clearance: 6-9%/year, HBsAg clearance: 0.5-1.6%/year) 
[34,35,48]. Second, ideally, we would have used maternal HBeAg status at the birth of the 
child as a proxy for mother-to-infant transmission, since maternal HBeAg positivity is a 
stronger predictor of maternal transmission than HBsAg. However, maternal sero-status was 
determined when the child entered the cohort, and by this time maternal HBeAg is likely to 
have been lost [8]. Third, the phases of the natural history of chronic HBV infection might 
have been incorrectly classified as they were determined on a single assessment rather than 
longitudinal monitoring. Fourth, HBV DNA was measured in historical samples, and its 
levels might have been affected by a prolonged storage and multiple freeze-thaw cycles. 
Nevertheless, the effect of freeze-thaw cycles is reported to be minimal for HBV DNA assays 
[49]. Finally, the HCC cases were ascertained through linkage with the cancer registry 
database, which is estimated to record only 50% of cases [50]. We attempted to mitigate this 
bias by also reviewing medical records at the local clinic. 
In conclusion, compared to East Asia, the natural history of chronic HBV infection in West 
Africa is characterized by a shorter duration of viremia and lower incidence of HCC, which is 
probably due to the lower frequency of mother-to-infant transmission in SSA. Among those 
who develop severe liver disease in The Gambia the majority are infected by their mothers, 
emphasizing the importance of interrupting perinatal transmission in SSA. 
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FIGURE LEGENDS 
Figure 1. Flow diagram of study participants 
 
Figure 2. Proportion of chronic HBV carriers who cleared HBeAg and HBsAg as a function 
of age* 
 
* The number at risk is smaller at 5 and 15 years than at 25 years in the figure for HBsAg 
because the median age of recruitment was 10.8 years. 
 
Figure 3. Changes with age in serum HBV DNA (A) and ALT levels (B) by maternal HBsAg 
status (- and + denote negative and positive maternal HBsAg, respectively) amongst chronic 
HBV carriers*  
 
* Two outliers (ALT: 166 and 351 IU/L) in positive maternal HBsAg group are not presented 
in the figure 3-B.  
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Supplementary Table 1. Participation, numbers who previously tested HBsAg-positive and number of newly identified HBsAg-positive in 
sero-surveys between 1974 and 2013.  
Year Target population Total tested Previously tested 
HBsAg-positive 
Newly 
identified in 
the current 
survey 
Laboratory tests performed 
Total Participated in the 
current survey (% 
follow-up) 
HBsAg HBeAg HBV 
DNA 
ALT 
1974 All villagers 1317 - - 136 RIA - - - 
1980 Children <15 years & 
mothers 
802 136 65 (48%) 104 RPHA1 RIA - - 
1984 Children <20 years 936 240 99 (41%) 143 RPHA
1
 RIA q-PCR Cobas Mira 
1985 Children <20 years 937 383 242 (63%) 4 RPHA
1
 RIA - - 
1989 Children <20 years & 
mothers 
1358 387 271 (70%) 49 RPHA1 RIA q-PCR - 
1992 HBsAg carriers 366 436 270 (62%) 1 RPHA1 RIA - Cobas Mira 
1993 Children <20 years & 
mothers 
1478 437 175 (40%) 30 RPHA
1
 RIA q-PCR - 
1998 HBsAg carriers & 
vaccinees 
1476 467 171 (37%) 12 RPHA
1
 RIA - - 
2003 All villagers 1640 479 294 (61%) 67 IC EIA q-PCR - 
2008 HBsAg carriers & 
vaccinees 
2078 546 323 (59%) 5 IC EIA q-PCR Vitros 
DT60-II 
2012-13 Carriers 332 551 332 (60%) 0 CMIA EIA q-PCR Vitros 350 
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Abbreviations: CMIA, chemiluminescent microparticle immunoassay; EIA, enzyme immunoassay; IC, immunochromatography; q-PCR, quantitative 
real-time polymerase chain reaction; RIA, radioimmunoassay; RPHA, reverse passive hemagglutination assay 
 
1 Positive results using RPHA were confirmed by neutralization with rabbit anti-HBs.
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Supplementary Table 2. Phases of the natural history of chronic HBV infection (adapted from 
the EASL/AASLD guidelines)
  
Phase HBsAg HBeAg HBV DNA 
(IU/ml) 
ALT (U/L) 
Immune tolerant phase Positive Positive ≥20,000 <40 
Chronic 
hepatitis B 
disease 
HBeAg-positive 
chronic hepatitis B 
Positive Positive Any ≥40 
HBeAg-negative 
chronic hepatitis B 
Positive Negative ≥2,000 ≥40 
Inactive HBV carrier state Positive Negative <2,000 <40 
Occult HBV infection Negative Negative Detectable Any 
Resolved hepatitis B Negative Negative Undetectable <40 
Unclassified HBeAg-positive Positive Positive <20,000 <40 
HBeAg-negative Positive Negative ≥2,000 <40 
<2,000 ≥40 
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Supplementary Table 3. Predictors of HBeAg sero-clearance (n=173) 
Variables Person-years  
 
No. of subjects 
cleared HBeAg 
Rate (% per 
annum) 
Crude RR Adjusted RR
3
 
RR (95% CI) p-value
1 
RR (95% CI)
 
p-value
1 
Sex Male 1231 86 7.0 1.0 (ref) 0.3 1.0 (ref) 0.3 
Female 682 56 8.2 1.2 (0.9 – 1.6)  1.2 (0.9-1.6)  
Current age 
group (years)
2
 
0-9 663 34 5.1 1.0 (ref) 0.02
 
1.0 (ref) 0.5 
10-19 761 66 8.7 1.7 (1.1 – 2.5)  1.4 (0.9-2.2)  
≥20 488 42 8.6 1.7 (1.1 – 2.6)  1.2 (0.7-1.9)  
Birthplace Keneba 869 67 7.7 1.0 0.6 1.0 (ref) 0.8 
Manduar 1043 75 7.2 0.9 (0.7 – 1.3)  1.0 (0.7-1.4)  
Maternal 
HBsAg 
Negative 1027 86 8.4 1.0 (ref) 0.1
 
1.0 (ref) 0.2 
Positive 673 43 6.4 0.8 (0.5 – 1.1)  0.8 (0.5 – 1.2)  
HBV DNA 
(IU/ml) at 
baseline2 
<2,000 333 31 9.3 1.0 (ref) 0.009 1.0 (ref) 0.02 
2,000-10
8
 601 51 8.5 0.9 (0.7-1.2)  1.0 (0.7-1.4)  
≥10
8
 930 56 6.0 0.6 (0.5-0.9)  0.7 (0.4-0.9)  
ALT (IU/L) at 
baseline 
<40 1736 129 7.4 1.0 (ref) 0.9 1.0 (ref) 0.7 
≥40 150 11 7.3 1.0 (0.6-1.5)  0.9 (0.6-1.5)  
1
 p-value and 95% CI were obtained by Wald test with robust standard error to take account of clustering among individuals who share the same mother. 
2
 Test for linear trend. 
3
 Rate ratio adjusted for sex, current age, calendar year and birthplace. 
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Supplementary Table 4. Predictors of HBsAg sero-clearance (n=405) 
Variables Person-years No. of subjects 
cleared HBsAg 
Rate (% per 
annum) 
Crude RR Adjusted RR
3
 
RR (95% CI) p-value
1 
RR (95% CI)
 
p-value
1 
Sex Male 4076 32 0.79 1.0 (ref) 0.05 1.0 (ref) 0.8 
Female 4426 53 1.20 1.5 (1.0 – 2.3)  1.1 (0.7-1.7)  
Current age 
group (years)
2 
0-9 957 1 0.10 1.0 (ref) <0.001 1.0 (ref) <0.001 
10-19 2189 10 0.46 4.4 (0.6 – 34.1)  5.5 (0.7-42.5)  
20-29 2382 24 1.01 9.6 (1.3 – 71.0)  16.2 (2.2-120.4)  
30-39 1528 16 1.05 10.0 (1.3 – 76.0)  16.6 (2.2-125.9)  
40-49 820 19 2.32 22.2 (3.0 – 165.7)  35.7 (4.8-264.2)  
50-70 627 15 2.39 22.9 (3.0 – 174.6)  42.5 (5.6-321.1)  
Birthplace Keneba 4344 49 1.13 1.0 (ref) 0.3 1.0 (ref) 0.3 
Manduar 4159 36 0.87 0.8 (0.5 – 1.2)  0.8 (0.5-1.2)  
Maternal 
HBsAg 
Negative 3913 27 0.69 1.0 (ref) 0.1
 
1.0 (ref) 0.1 
Positive 2006 7 0.35 0.5 (0.2 – 1.2)  0.5 (0.2 – 1.2)  
HBeAg at 
baseline 
Negative 4353 51 1.17 1.0 (ref) <0.001 1.0 (ref) 0.3 
Positive 4000 16 0.40 0.3 (0.2-0.6)  0.7 (0.3-1.3)  
HBV DNA 
(IU/ml) at 
baseline
2 
<2,000 4490 68 1.52 1.0 (ref) <0.001 1.0 (ref) 0.03 
2,000-10
8
 2111 9 0.43 0.3 (0.1-0.5)  0.5 (0.2-1.0)  
≥108 1776 5 0.28 0.2 (0.1-0.4)  0.4 (0.2-1.2)  
ALT (IU/L) at 
baseline 
<40 8066 79 0.98 1.0 (ref) 0.9 1.0 (ref) 1.0 
≥40 339 3 0.88 0.9 (0.3-2.9)  1.0 (0.3-3.6)  
1
 p-value and 95% CI were obtained by Wald test with robust standard error to take account of clustering among individuals who share the same mother. 
2
 Test for linear trend. 
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3 Rate ratio adjusted for sex, current age, calendar year and birthplace. 
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Supplementary Table 5. Characteristics of individuals who died of ESLD (includes HCC and non-malignant ESLD) 
Cause of death Age at 
enrolment 
Age at 
diagnosis 
Sex Birth 
place 
Maternal 
HBsAg 
HBeAg at 
baseline 
HBV DNA at 
baseline (IU/ml) 
ALT at 
baseline (IU/L) 
HBsAg loss during 
follow-up 
HCC 43 45 M Keneba N/A Negative N/A N/A No 
HCC1 29 67 M Manduar N/A Negative 2,800 43 No 
HCC 23 57 M Manduar N/A Negative N/A 13 No 
HCC 20 50 M Manduar Positive Negative 1,345,000
 
10 No 
HCC 21 42 M Manduar Positive Positive 300,000
 
15 No 
HCC 21 38 M Manduar N/A Negative N/A N/A Yes 
Non-malignant 
ESLD 
21 57 M Keneba N/A Negative N/A 6 No 
Non-malignant 
ESLD 
7 19 F Keneba Positive Positive N/A 8 No 
1
 This patient had genotype A. 
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Supplementary Table 6. Predictors of geometric mean HBV DNA and mean ALT levels (n=405) 
Variables HBV DNA levels  ALT levels 
Geometric mean 
HBV DNA (IU/ml) 
Adjusted ratio of geometric 
mean HBV DNA (95% CI)
1,3 
p-value
1
 Mean ALT 
(IU/L) 
Adjusted mean 
difference (95% CI)
1,3
 
p-value
1
 
Sex Male 10,093 1.0 (ref) 0.04 21.0 0.0 (ref) 0.01 
Female 916 0.5 (0.3 – 0.7)  18.7 -3.5 (-6.3 – 0.8)  
Current age 
group (years)
2 
0-9 6,505,734 1.0 (ref) <0.001
 
10.9 0.0 (ref) <0.001
 
10-19 36,785 4x10
-3
 (2x10
-3
 – 9x10
-3
)  15.3 5.8 (1.4 – 10.2)  
20-29 947 1x10-4 (4x10-5 – 2x10-4)  25.3 14.8 (10.3 – 19.4)  
30-39 318 3x10-5 (1x10-5 – 7x10-5)  23.4 17.1 (12.8 – 21.4)  
40-49 170 7x10
-6
 (2x10
-6
 – 2x10
-5
)  21.8 20.3 (14.5 – 26.0)  
50-70 145 2x10
-6
 (4x10
-7
 – 1x10
-5
)  20.5 28.2 (21.3 – 35.0)  
Birthplace Keneba 1,723 1.0 (ref) 0.6 20.6 0.0 (ref) 0.4 
Manduar 5,704 1.2 (0.6 – 2.2)  18.9 -1.2 (-3.9 – 1.4)  
Maternal HBsAg Negative 3,607 1.0 (ref) <0.001 17.6 0.0 (ref) 0.005
 
Positive 21,499 4.7 (2.0 – 11.1)  22.5 4.0 (1.2 – 6.8)  
1 Mean difference, p-value and 95% CI estimated using a linear mixed models to account for repeated measurements within participants. 
2 Test for linear trend. 
3 Mean difference adjusted for sex, current age, age at study entry and birthplace. 
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Supplementary Figure 1. Age-specific prevalence of HBeAg in chronic HBV carriers at baseline 
(n=405) 
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Supplementary Figure 2. Proportion of chronic HBV carriers who cleared HBeAg (A) and 
HBsAg (B) as a function of age and according to maternal HBsAg positivity* 
 
* The number at risk is smaller at 5 years than at 15 years in supplementary figure 2-B because the 
median age of recruitment was 10.8 years.  
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Supplementary Figure 2-B 
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Supplementary Figure 3. Changes in phase of natural history between baseline (n=405) and 
2012-2013 liver assessment (n=301) 
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